Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Hodgkin’s lymphoma survivors carry high disease burden from SMN, CVD

11 Apr 2018

Survivors of Hodgkin’s lymphoma (HL) are at greater risk of developing subsequent malignant neoplasm (SMN) and cardiovascular disease (CVD), according to a study.

The study included 2,908 5-year HL survivors (median age at treatment, 27.3 years). Majority of patients were treated with radiotherapy alone (27.1 percent) or in combination with chemotherapy (65.9 percent). Among those who underwent radiotherapy, 25.7 percent received subtotal nodal irradiation, 24.5 percent received mantle field irradiation and 16.2 percent received other supradiaphragmatic radiation fields.

Over a median follow-up of 22 years, 888 survivors developed SMNs and 1,153 developed CVDs. The 40-year cumulative incidence of developing either SMN or CVD was 68 percent, while that of developing both SMN and CVD was 17 percent. The mean cumulative count of all SMN and CVD events was 1.2 events per patient.

Survivors who developed a solid malignancy had similar 15-year risk of developing another subsequent malignancy vs a CVD (15 percent vs 15 percent). On the other hand, survivors who developed a CVD had a higher 15-year risk of developing another CVD vs a subsequent malignancy (46 percent vs 15 percent).

On multivariable Cox regression analysis, radiotherapy emerged as the strongest risk factor for developing both SMN and CVD.

Researchers pointed out that HL survivors diagnosed with SMN or CVD also have a high risk of subsequent events, highlighting the importance of an expertise in cardio-oncology in the follow-up care of this population.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.